Stock Events

Stock Events

Cognition Therapeutics 

$1.4650
105
+$0.21+16.27% Today

Statistics

Day High
1.47
Day Low
1.25
52W High
3.83
52W Low
0.25
Volume
102,863,535
Avg. Volume
-
Mkt Cap
129.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.25
-0.18
-0.12
-0.05
Expected EPS
-0.0625
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-67.94MNet Income

Analyst Ratings

4.00Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.53B
Biogen is a leading biotech company in the Alzheimer's disease space, directly competing with Cognition Therapeutics' focus on neurodegenerative disorders.
Lilly(Eli) &
LLY
Mkt Cap1.01T
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Cognition Therapeutics.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.61B
Acadia Pharmaceuticals has products and a pipeline targeting central nervous system disorders, including Alzheimer's, making it a competitor.
Anavex Life Sciences
AVXL
Mkt Cap231.68M
Anavex Life Sciences Corp. is working on developing treatments for Alzheimer's disease, directly competing with Cognition Therapeutics.
Axsome Therapeutics
AXSM
Mkt Cap13.13B
Axsome Therapeutics is involved in developing therapies for central nervous system disorders, including cognitive disorders, making it a competitor.
Prothena
PRTA
Mkt Cap426.68M
Prothena Corporation plc is focused on the development of treatments for neurodegenerative diseases, including Alzheimer's, competing with Cognition Therapeutics.
AnaptysBio
ANAB
Mkt Cap1.63B
AnaptysBio, Inc. is developing treatments for neuroinflammatory diseases, indirectly competing with Cognition Therapeutics in the broader neurodegenerative disease market.

About

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Show more...
CEO
Ms. Lisa Ricciardi
Employees
25
Country
United States
ISIN
US19243B1026

Listings

XNAS
US
CGTX
BOATS
BOATS
CGTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Cognition Therapeutics stock price today?▼
The current price of CGTX is $1.47 USD — it has increased by +16.27% in the past 24 hours. Watch Cognition Therapeutics stock price performance more closely on the chart.
What is Cognition Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cognition Therapeutics stocks are traded under the ticker CGTX.
Is Cognition Therapeutics stock price growing?▼
CGTX stock has risen by +25.88% compared to the previous week, the month change is a +25.88% rise, over the last year Cognition Therapeutics has showed a +412.5% increase.
What is Cognition Therapeutics market cap?▼
Today Cognition Therapeutics has the market capitalization of 129.32M
When is the next Cognition Therapeutics earnings date?▼
Cognition Therapeutics is going to release the next earnings report on August 11, 2026.
What were Cognition Therapeutics earnings last quarter?▼
CGTX earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.07 USD resulting in a +25.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cognition Therapeutics revenue for the last year?▼
Cognition Therapeutics revenue for the last year amounts to 0 USD.
What is Cognition Therapeutics net income for the last year?▼
CGTX net income for the last year is -67.94M USD.
How many employees does Cognition Therapeutics have?▼
As of June 17, 2026, the company has 25 employees.
In which sector is Cognition Therapeutics located?▼
Cognition Therapeutics operates in the Health & Wellness sector.
When did Cognition Therapeutics complete a stock split?▼
Cognition Therapeutics has not had any recent stock splits.
Where is Cognition Therapeutics headquartered?▼
Cognition Therapeutics is headquartered in Purchase, United States.